Etcamah

ATC：L02BA05

治疗领域：Breast Neoplasms

药理分类：Endocrine therapy

修订号：— · 最新影响 PI 的程序：—

适应症（原文）：Etcamah in combination with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) is indicated for the treatment of adult patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1‑mutation and without disease progression during first-line endocrine therapy in combination with a CDK4/6 inhibitor (for biomarker based patient-selection, see section 4.2 and 5.1).